Core Insights - Cosmos Health Inc. is at a pivotal moment, having refined its strategy and operations to foster sustainable growth and long-term value creation [1][3] - The company aims to create a global healthcare platform integrating various sectors, including pharmaceuticals, nutraceuticals, and digital finance [4][5] - The ambition for 2030 is to transform into a global powerhouse by scaling branded products and leveraging AI and blockchain technologies [6][7] Vision & Ambition - The company has aligned all business units towards a common goal of making high-quality healthcare accessible globally [4][5] - Cosmos Health emphasizes resilience, creativity, and leadership in rapidly evolving industries [5] Milestones & Achievements - Significant progress has been made in financing, manufacturing capabilities, and innovation pipeline, including securing a $300 million financing facility [9][11] - The company has expanded its manufacturing footprint and strengthened its wholesale operations [10][18] Financial Performance & Outlook - In 2024, Cosmos Health reported revenues of approximately $54.43 million, a 2% increase from 2023, with a notable reduction in operating expenses [40][41] - The company aims for continued growth and profitability, targeting approximately $155.8 million in revenue by 2027 [48][44] Strategy & Roadmap - The growth strategy is built on six pillars, focusing on profitability, cash flow, and scaling high-margin businesses [46] - The company is committed to maintaining financial strength while pursuing innovation and global expansion [49][52] R&D and Innovation - Cosmos Health is advancing its proprietary obesity treatment, CCX0722, and expanding its R&D pipeline across multiple therapeutic areas [25][30] - The company utilizes its AI-enabled platform, Cloudscreen, to enhance drug discovery and accelerate innovation [26][50] Global Expansion - The flagship brand, Sky Premium Life, is expanding internationally, with over 150 premium products and strong demand across various regions [18][19] - The company has established a dual manufacturing hub in the U.S. and Europe to enhance supply chain resilience [18][22] Insider Commitment - The CEO has invested over $18 million of personal capital into the company, demonstrating a strong alignment of interests with shareholders [34][35] Sustainability Commitment - Cosmos Health is focused on balancing growth with social responsibility, emphasizing innovation, market development, and digital asset strategies [53][54]

CHICAGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”), has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL® pessaries, further expanding its pipeline of pharmaceutical products. Under the terms of the agreement, Cana will manufacture MYCOFAGYL®, a combination of Metron ...

CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its proprietary Sky Premium Life food supplements brand. All Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excell ...

Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and focuses on the R&D of novel patented nutraceuticals and innovative OTC products [6] Recent Developments - Cosmos Health's subsidiary, Sky Pharm SA, signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman [1][3] - Scientific Pharmacy is a leading healthcare and beauty company in Oman, known for its strong customer focus and international brand partnerships [2] - The agreement includes an initial purchase order of 42,000 units, with Scientific Pharmacy managing all core activities related to the distribution and marketing of the products [3] Market Insights - The GCC nutraceuticals market was valued at $6.91 billion in 2024 and is projected to reach $15.5 billion by 2033, with a compound annual growth rate (CAGR) of 8.7% [4] - Growth in the nutraceuticals market is driven by rising health awareness, higher disposable incomes, government initiatives addressing lifestyle diseases, rapid urbanization, and the expansion of retail and e-commerce channels [4] Strategic Outlook - The CEO of Cosmos Health expressed excitement about the expansion into Oman, highlighting the potential for significant revenue generation supported by Scientific Pharmacy's established network [5] - The agreement is seen as a milestone that showcases the quality of Cosmos Health's products and the increasing global demand for the Sky Premium Life brand [5]

Financial Performance - Cosmos Health reported Q2 2025 revenue of $14.75 million, an increase of 11.66% from $13.21 million in Q2 2024, and a total revenue of $28.46 million for the first half of 2025, up 2.4% from $27.79 million in the prior-year period [5][6] - Gross profit for Q2 2025 rose 51.60% year-over-year to $1.16 million, compared to $0.77 million in Q2 2024, while gross profit for the first half of 2025 increased 53.0% to $3.21 million from $2.10 million [5][6] - The gross margin expanded by 208 basis points to 7.89% in Q2 2025 and by 374 basis points to 11.30% for the first half of 2025 [5][6] Balance Sheet Strength - Total assets increased by 13.9% to $61.84 million as of June 30, 2025, up from $54.31 million at year-end 2024, reflecting enhanced liquidity and a diversified asset base [2][5] - Stockholders' equity rose to $26.23 million from $24.53 million at year-end 2024, indicating a stronger capital base [2][5] - The liabilities-to-assets ratio remained at 57.6%, demonstrating continued financial discipline [2] Management Insights - CEO Greg Siokas expressed satisfaction with the Q2 results, highlighting double-digit revenue growth, significant gross profit increase, and ongoing gross margin expansion [3][5] - The company is focused on driving efficiencies across its business to achieve cash flow positive status, which is seen as a key turning point [4][5] Future Growth Initiatives - Cosmos Health announced a financing facility of up to $300 million aimed at building a portfolio of digital assets and providing growth capital for expansion plans [6][5] - The company has already initiated purchases of Ethereum as part of leveraging this facility to enhance its position in the crypto space [6]

Core Viewpoint - Cosmos Health Inc. has initiated the purchase of Ethereum (ETH) as part of its digital asset treasury reserve strategy, marking a significant step towards integrating cryptocurrency into its financial strategy [1][2]. Group 1: Company Strategy - The company has completed an initial purchase of $1 million in ETH, utilizing a financing facility of up to $300 million with a U.S.-based institutional investor [1]. - CEO Greg Siokas expressed enthusiasm about building an ETH treasury, indicating a shift from holding only cash to incorporating assets with strong appreciation potential [2]. - The strategic move is supported by the growing adoption of ETH by institutional investors, its inclusion in ETFs, and the proposed expansion of cryptocurrency access in retirement plans [2]. Group 2: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3]. - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates under European Good Manufacturing Practices (GMP) [3]. - Cosmos Health is expanding its global distribution platform and has established R&D partnerships targeting major health disorders, enhanced by AI drug repurposing technologies [3].

Financing & Strategy - Cosmos Health 获得 3 亿美元融资 [1] - 公司计划启动以太坊（$ETH）金库策略 [1] Market Sentiment - 市场普遍看涨以太坊（$ETH）[1]

Core Insights - Cosmos Health Inc. has entered into a securities purchase agreement for the issuance of up to $300 million in senior secured convertible promissory notes to support its Ethereum digital asset treasury reserve strategy [1][3] - The financing is seen as a strategic milestone, providing shareholders with direct exposure to Ethereum, which is one of the most widely adopted digital assets [3] - At least 72.5% of the net proceeds from each tranche will be allocated to building the digital asset treasury reserve, with the remainder for working capital and growth initiatives [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [5] - The company manufactures pharmaceuticals and food supplements under European Good Manufacturing Practices and distributes a broad line of pharmaceuticals and parapharmaceuticals in Greece and the UK [5] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [5] Strategic Initiatives - The company plans to strategically accumulate Ethereum to enhance long-term shareholder value through increasing ETH-per-share [6] - ETH assets will be custodied and staked through institutional infrastructure provided by BitGo Trust Company [6] - The treasury initiative complements ongoing digital transformation and e-commerce efforts, with potential exploration of blockchain use cases in supply chain traceability and global consumer engagement [6]

Core Insights - Cosmos Health Inc. has announced its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC [1][2] - The production will take place in GMP-certified facilities, enhancing operational control and reducing tariff exposure [2][4] - This partnership aims to strengthen Cosmos Health's position in the premium nutraceuticals market and expand its portfolio with scientifically backed ingredients [3][4] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, owning proprietary pharmaceutical and nutraceutical brands and operating a telehealth platform [6] - The company has established R&D partnerships targeting major health disorders and focuses on innovative product development [6] - Cosmos Health has a global distribution platform and is expanding throughout Europe, Asia, and North America [6] Partnership Details - The agreement with DolCas Biotech is expected to leverage DolCas's expertise in clinically validated formulations and vertically integrated manufacturing [3][4] - DolCas Biotech is recognized for its commitment to quality and innovation, with a portfolio that includes clinically supported nutraceutical products [5] - The partnership is seen as a strategic move to support Cosmos Health's growth in the U.S. and globally [4]

Core Viewpoint - Cosmos Health Inc. reported a strong financial performance for Q1 2025, showcasing a significant turnaround with improved profitability metrics and disciplined cost management. Financial Highlights - Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, attributed to a strategic shift towards higher-margin areas [6] - Gross profit increased by 53.70% to $2.05 million from $1.33 million in the prior-year period, driven by an improved product mix [6] - Adjusted EBITDA rose by 157.8% to $0.37 million compared to a loss of $0.64 million in Q1 2024 [6] - Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period [6] Profitability and Cost Management - The company achieved profitability on an adjusted basis for both EBITDA and Net Income, reflecting improved gross profitability and effective cost management [3][9] - Total operating expenses declined by 9.05% to $2.88 million, with significant reductions in salaries and wages (17.34%) and sales and marketing expenses (83.78%) [6] Balance Sheet and Cash Flow - Stockholders' equity increased by $1.42 million, with a liabilities-to-assets ratio of 54.6%, indicating financial discipline [5] - Total assets rose by 5.3% to $57.2 million, while total liabilities increased by 4.9% to $31.24 million [7] - Operating cash burn improved by 94.5% year-over-year, decreasing to negative $0.19 million from negative $3.41 million in Q1 2024 [8] Operational Developments - The wholesale logistics segment (CosmoFarm) and the nutraceutical and pharmaceutical products portfolio, including Sky Premium Life®, were key contributors to the strong performance [4] - The company is advancing its R&D pipeline, with projects like the CCX0722 weight management solution nearing launch [11] - Cosmos Health is expanding its high-margin contract manufacturing segment and growing its flagship nutraceutical brand, Sky Premium Life, in global markets [11]